Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
The Global 3D Cell Culture Market is expected to witness a double-digit growth rate by 2027. Some of the key factors dri…
The human skin is something we tend not to give much thought to, but even superficial studies shows it to be a complex a…
The increasingly widespread digital connectivity of medical infrastructure is giving rise to complex systems with hosts…
The 2023 SCADA Awards(Student Competition for Advancing Dental Research and its Application), co-sponsored by Dentsply S…
. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to…
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized contro…
. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indic…
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 m…
The demand for hyperbaric oxygen therapy devices has been increasing significantly with rising prevalence of wound infec…